A review on response of immune system in spinal cord injury and therapeutic agents useful in treatment.
Every year more than 12,000 people in US alone suffer from spinal cord injury. However, complete recovery of physical function is difficult due to multiple factors involved in disease progression. Currently available therapeutic regimens do not address all the factors concerned with the disease progression. The present review focuses mainly on the role of immune cells in progression of spinal cord injury and the drugs that target these immune cells. Literature search shows that inflammatory reactions and subsequent reactions that follow direct injury to spinal cord are sometimes responsible for the severity of the disease. Therefore, for design of proper treatment regimen a deep understanding in this area is required. Understanding the pathophysiology will help in creating delivery system that can target multiple factors involved in progression of spinal cord injury. A combination of various treatment strategies is required to reduce the disability in patients with spinal cord injury.
Narayanan
N
Kasinathan
Meenashi B
MB
Vanathi
Volety M
VM
Subrahmanyam
Department of Pharmaceutical Biotechnology, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal- 576104, Manipal, India. vm.subra@manipal.edu.
Josyula V
JV
Rao
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000818:Animals; D017209:Apoptosis; D015551:Autoimmunity; D002921:Cicatrix; D006801:Humans; D009457:Neuroglia; D015427:Reperfusion Injury; D013119:Spinal Cord Injuries / Q000188:drug therapy / Q000276:immunology*; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology
D000276:Adjuvants, Immunologic